Spironolactone: Renaissance of antialdosterone therapy in heart failure;Spironolacton: Renaissance der Antialdosterontherapie bei Herzinsuffizienz?

Praxis

Volumn 86, Issue 14, 1997, Pages 566-574

  Brilla, Ch G ^a   Schencking, M ^a   Scheer, Ch ^a   Rupp, H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

aldosterone fibrosis; heart failure; spironolactone

Indexed keywords

DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METALLOPROTEINASE; SPIRONOLACTONE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE; HUMAN; HYPERALDOSTERONISM; MORBIDITY; MORTALITY; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030905038     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Kannel W. B.: Epidemiological aspects of heart failure. In: Heart Failure: Current Concepts and Management. K.T. Weber (Hrsg.) Cardiol Clinics 7, 1-9, 1989.
2. Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316, 1429-1435, 1987.
3. Cohn J. N., Johnson G., Ziesche S. et al.: A comparison of enalapril with hydralazine-isosorhide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325, 303-310, 1991.
4. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325, 293-302, 1991.
5. Levy D., Garrison K. J., Savage D. D., Kannel W. R., Castelli W. P.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322, 1561-1566, 1990.
6. Brilla C. C., Pick R., Tan L. B., Janicki J. S., Weber K. T.: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 67, 1355-1364, 1990.
7. Brilla C. G., Maisch R.: Regulation of the structural remodeling of the myocardium: from hypertrophy to heart failure. Europ Heart J 15 (Suppl D), 45-52, 1994.
8. Brilla C. G., Weber K. T.: Reactive and reparative myocardial fihrosis in arterial hypertension. Cardiovasc Res 26, 671-677, 1992.
9. Weber K. T., Brilla C. G.: Pathologic hypertrophy and the cardiac interstitium: Fibrosis and the renin-angiotensin-aldosterone system. Circulation 83, 1849-1865, 1991.
10. Brilla C. G., Janicki J. S., Weber K. T.: Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 83, 1771-1779, 1991.
11. Brilla C. G., Matsubara L., Weber K. T.: Advanced hypertensive heart disease in spontaneously hypertensive rats: Lisinopril-mediated regression of myocardial fibrosis. Hypertension 28, 269-275, 1996.
12. Brilla C. G., Matsubara L. S., Weber K. T.: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25, 563-575, 1993.
13. Young M., Fullerton M., Dilley R., Funder J.: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93, 2578-2583, 1994.
14. Weber K. T., Anversa P., Armstrong P. W., Brilla C. G., Burnett J. C., Cruickshank J. M., Devereux R. B., Giles T. D., Korsgaard N., Leier C. V., Mendelsohn F. A. O., Motz W. H., Mulvany M. J., Strauer B. E.: Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20, 3-16, 1992.
15. Packer M.: Neurohormonal interactions and adaptations in congestive heart failure. Circulation 77, 721-730, 1988.
16. Harris P.: Evolution and the cardiac patient. Cardiovasc Res 17, 437-445, 1983.
17. Brilla C. G., Zhou G., Myers P. R., Weber K. T.: Angiotensin II-mediated aldosterone synthesis in cultured bovine aortic endothelial cells. J Hypertens 10 (Suppl 4), S75, 1992.
18. Takeda R., Hatakeyama H., Takeda Y., Kazuhiro I., Miyamori I., Sheng W. P., Yamamoto H., Blair I. A.: Aldosterone biosynthesis and action in vascular cells. Steroids 60, 120-124, 1995.
19. Meyer W. J. III, Nichols N. R.: Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta. J Steroid Biochem 14, 1157-1168, 1981.
20. Köhler E., Bertschin S., Woodtli T., Resink T., Erne P.: Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 33, 315-326, 1996.
21. Komuro I., Kaida T., Shibazaki Y., Kurabayashi M., Katoh Y., Huh K., Takaku F., Yuzaki Y.: Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem 265, 3595-3598, 1990.
22. Caidahl K., Eriksson H., HartfordM., Wikstrand J., Wallentin I., Arvidsson A., Svärdsudd K.: Dyspnoe of cardiac origin in 67 year old men: (2) relation to diastolic left ventricular function and mass. The study of men horn in 1913. Br Heart J 59, 329-338, 1988.
23. Burtosova D., Chvapil M., Korecky B., Poupa O., Rakusan K., Turek Z., Vizek M.: The growth of the muscular and collagenous parts of the rat heart in various forms of cardiomegaly. J Physiol 200, 185-195, 1969.
24. Robert V., Van T. N., Cheav S. L., Mauas C, Swynghedauw B., Delcayre C.: Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 24, 30-36, 1994.
25. Rrilla C. G., Zhou G., Matsubara I., Weber K. T.: Collagen metabolism in cultured aduli rat cardiac fibrohlasts: response to angiotensm Il and aldosterone. J Mol Cell Cardiol 26, 809-820, 1994.
26. Brilla C. G., Maisch K., Zhou G., Weber K. T.: Hormonal regulation of cardiac fibroblast function. Europ Heart J 16 (Suppl C). 45-50, 1995.
27. Sadoshima J., Izumo S.: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the ATI receptor subtype. Circ Res 73, 413-423, 1993.
28. Villarreal F. J., Kim N. N., Ungab G. D., Printz M. P., Dillmann W. H.: Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 88, 2849-2861, 1993.
29. Katwa L. C., Weber K. T.: Aldosterone-induced expression of ET1, ET3 and ETB receptors by cultured adult rat cardiac fibroblasts. Abstract. Circulation 94.1-146, 1996.
30. Diegelmann R. E, Cohen I. K., McKoy B. J.: Growth kinetics and collagen synthesis of normal skin, normal scar and keloid fibroblasts in vitro. J Cell Physiol 98, 341-346, 1979.
31. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821-828, 1993.
32. Pitt B.: ≪Escape≫ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 9, 145-149, 1995.
33. Dahlström U., Karlsson E.: Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 71, 29A-33A, 1993.
34. Van Vliet A. A., Danker A. J., Nauta J. J., Verheugt F. W.: Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 71, 21A-28A, 1993.
35. Ya-ling H., Ming T., Quan-min J., Xiao-ling H., Ji-qing L.: Combined therapy of captopril and spironolactone for refractory congestive heart failure. Chinese Med J 107, 688-692, 1994.
36. The RALES Investigators: Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78, 902-907, 1996.
37. Brilla C. G., Düsing R., Hausdorf K., Ibrahim Z., Kromer K. P., Spitzer W.: Aldosteron-Antagonisten hei der Herzinsuffizienz: Renaissance einer altbewährten Therapie. Internist 36, A30-A31, 1995.
38. Brilla C. G.: Hochdruck und hypertensive Herzkrankheit: Pathophysiologie. Klinik, Diagnostik und Therapie. Berlin: Walter de Gruyter Verlag, 1994.